Robeco Institutional Asset Management B.V. Trims Stock Position in Amgen Inc. (NASDAQ:AMGN)

Robeco Institutional Asset Management B.V. reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 419,178 shares of the medical research company's stock after selling 36,427 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.08% of Amgen worth $109,255,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new position in Amgen in the third quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the 3rd quarter worth about $29,000. Matrix Trust Co acquired a new stake in shares of Amgen during the 3rd quarter worth about $36,000. Livelsberger Financial Advisory purchased a new stake in Amgen during the third quarter worth approximately $56,000. Finally, Icon Wealth Advisors LLC boosted its holdings in Amgen by 3,955.0% in the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company's stock valued at $56,000 after purchasing an additional 169,748 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Amgen stock traded up $1.38 during midday trading on Wednesday, reaching $281.68. The company's stock had a trading volume of 2,451,855 shares, compared to its average volume of 3,042,614. The stock's 50 day simple moving average is $271.48 and its 200 day simple moving average is $305.15. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $151.41 billion, a PE ratio of 36.07, a P/E/G ratio of 2.78 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period last year, the company posted $4.96 earnings per share. On average, equities research analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.38%. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen's payout ratio is presently 115.24%.

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. Wolfe Research started coverage on shares of Amgen in a report on Friday, November 15th. They issued a "peer perform" rating for the company. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Leerink Partners decreased their target price on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Piper Sandler Companies restated an "overweight" rating and set a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Amgen has an average rating of "Hold" and a consensus target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.